Karen E. Knudsen

Q: What Schools Are Affiliated With Karen E. Knudsen

Karen E. Knudsen is affiliated with the following schools: University of Cincinnati, University of New South Wales, University of Trento, University of Massachusetts Medical School, Gachon University, Johns Hopkins University, University of California, San Francisco, Thomas Jefferson University, University of Pennsylvania, Monash University

Karen E. Knudsen's AcademicInfluence.com Rankings

Karen E. Knudsen

Medical

#683

World Rank

#908

Historical Rank

Oncology

#33

World Rank

#35

Historical Rank

medical Degrees

Download Badge

Medical

Karen E. Knudsen's Degrees

PhD Molecular Biology University of California, San Francisco
Doctorate Medicine Johns Hopkins University

Why Is Karen E. Knudsen Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Karen E. Knudsen is Chief Executive Officer of American Cancer Society and its advocacy affiliate the American Cancer Society Cancer Action Network. She is the first woman to hold that position in either organization.

(See a Problem?)

Karen E. Knudsen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. (2015) (1670)
Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. (2007) (705)
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (2018) (398)
Transcriptional silencing of Ty1 elements in the RDN1 locus of yeast. (1997) (387)
Cyclin D1: polymorphism, aberrant splicing and cancer risk (2006) (383)
Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs (2015) (372)
AR, the cell cycle, and prostate cancer (2008) (338)
Tailoring to RB: tumour suppressor status and therapeutic response (2008) (331)
Dual roles of PARP-1 promote cancer growth and progression. (2012) (321)
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. (2010) (302)
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer (2009) (297)
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer (2010) (291)
A hormone-DNA repair circuit governs the response to genotoxic insult. (2013) (274)
An evaluation of evidence for the carcinogenic activity of bisphenol A. (2007) (273)
BRG-1 is required for RB-mediated cell cycle arrest. (2000) (264)
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. (2014) (249)
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. (2011) (246)
RB-Dependent S-Phase Response to DNA Damage (2000) (233)
Multiple G1 Regulatory Elements Control the Androgen-dependent Proliferation of Prostatic Carcinoma Cells* (1998) (207)
The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. (2002) (205)
D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. (1999) (203)
N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. (2007) (202)
The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. (2011) (193)
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. (2007) (192)
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. (2017) (191)
Prostate cancer (2021) (181)
Beyond DNA repair: DNA-PK function in cancer. (2014) (174)
FOXA1: master of steroid receptor function in cancer (2011) (171)
RB-pathway disruption in breast cancer (2010) (161)
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. (2017) (160)
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. (2017) (155)
Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy (2014) (151)
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance (2019) (149)
Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. (2010) (146)
The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc12 (2014) (146)
Cyclin D1: Mechanism and Consequence of Androgen Receptor Co-repressor Activity* (2002) (145)
Speedy: a novel cell cycle regulator of the G2/M transition (1999) (144)
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation (2006) (141)
DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. (2015) (137)
BAF57 Governs Androgen Receptor Action and Androgen-Dependent Proliferation through SWI/SNF (2005) (132)
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. (2020) (129)
Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors12 (2015) (126)
Transcriptional Roles of PARP1 in Cancer (2014) (123)
Hus1p, a conserved fission yeast checkpoint protein, interacts with Rad1p and is phosphorylated in response to DNA damage (1998) (122)
Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. (2005) (117)
Compensation of BRG-1 Function by Brm (2002) (116)
Ex vivo culture of human prostate tissue and drug development (2013) (114)
Differential Requirement of SWI/SNF for Androgen Receptor Activity* (2003) (112)
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. (2015) (111)
Retinoblastoma Tumor Suppressor: Where Cancer Meets the Cell Cycle (2006) (110)
Molecular pathogenesis and progression of prostate cancer. (2013) (109)
Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors (2012) (108)
Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. (2009) (107)
Targeting cell cycle and hormone receptor pathways in cancer (2013) (106)
Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer (2015) (99)
DNA methylation landscapes in advanced prostate cancer (2020) (98)
Cancer and the Circadian Clock. (2019) (97)
2,3,7,8-Tetrachlorodibenzo-p-dioxin Blocks Androgen-Dependent Cell Proliferation of LNCaP Cells through Modulation of pRB Phosphorylation (2004) (90)
USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. (2014) (90)
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. (2017) (89)
Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer (2009) (86)
Cyclin A Is a Functional Target of Retinoblastoma Tumor Suppressor Protein-mediated Cell Cycle Arrest* (1999) (83)
Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome (2009) (82)
Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import (2018) (82)
The cyclin D1b splice variant: an old oncogene learns new tricks (2006) (81)
Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. (2007) (78)
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer (2018) (77)
Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. (2008) (77)
Androgen receptor corepressors and prostate cancer. (2006) (76)
Specificity of cyclin D1 for androgen receptor regulation. (2003) (76)
The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. (2008) (75)
Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer (2006) (74)
Impact of differential cyclin D1 expression and localisation in prostate cancer (2007) (74)
The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death (1999) (73)
A patient‐derived explant (PDE) model of hormone‐dependent cancer (2018) (72)
Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. (2005) (72)
Differential impact of RB status on E2F1 reprogramming in human cancer (2017) (71)
The Epigenetic Modifier Ubiquitin-specific Protease 22 (USP22) Regulates Embryonic Stem Cell Differentiation via Transcriptional Repression of Sex-determining Region Y-box 2 (SOX2)* (2013) (71)
Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. (2008) (70)
Retinoblastoma Tumor Suppressor Protein Signals through Inhibition of Cyclin-Dependent Kinase 2 Activity To Disrupt PCNA Function in S Phase (2001) (70)
AR function in promoting metastatic prostate cancer (2014) (69)
Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells (2018) (66)
A central domain of cyclin D1 mediates nuclear receptor corepressor activity (2005) (66)
Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. (2010) (64)
The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc (2020) (62)
Targeting p300/CBP axis in lethal prostate cancer. (2021) (62)
Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing (2018) (61)
Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. (2010) (57)
PARP Inhibitors in Prostate Cancer (2017) (57)
RB Loss Promotes Prostate Cancer Metastasis. (2017) (56)
Endocrine disrupting compounds and prostate cancer. (2006) (55)
Elevated cyclins and cyclin-dependent kinase activity in the rhabdomyosarcoma cell line RD. (1998) (55)
Cellular rewiring in lethal prostate cancer: the architect of drug resistance (2020) (55)
The meaning of p16ink4a expression in tumors (2011) (55)
Expression of E-, P-, n-cadherins and catenins in human bladder carcinoma cell lines. (2000) (53)
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer (2011) (53)
Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. (2017) (52)
Linking DNA Damage and Hormone Signaling Pathways in Cancer (2016) (51)
Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. (2013) (51)
PARP‐1 regulates DNA repair factor availability (2018) (49)
Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. (2014) (49)
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer (2011) (48)
Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039)) (2018) (48)
Cyclin D1 Is a Selective Modifier of Androgen-dependent Signaling and Androgen Receptor Function* (2011) (47)
Unique Bisphenol A Transcriptome in Prostate Cancer: Novel Effects on ERβ Expression That Correspond to Androgen Receptor Mutation Status (2007) (44)
Models of neuroendocrine prostate cancer. (2014) (44)
The DNA methylation landscape of advanced prostate cancer (2020) (44)
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (2018) (44)
Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. (2016) (43)
Functional Specificities of Brm and Brg-1 Swi/Snf ATPases in the Feedback Regulation of Hepatic Bile Acid Biosynthesis (2009) (42)
The AR dependent cell cycle: Mechanisms and cancer relevance (2012) (42)
Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells. (2000) (42)
Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. (2013) (41)
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer (2011) (40)
Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression (2015) (38)
Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. (2014) (37)
Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. (2018) (37)
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair (2021) (37)
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer (2018) (35)
The Complex Role of AR Signaling After Cytotoxic Insult: Implications for Cell Cycle Based Chemotherapeutics (2007) (35)
Cyclin D3 action in androgen receptor regulation and prostate cancer (2008) (34)
Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. (2012) (32)
Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes (2013) (32)
Cell-cycle coupled expansion of AR activity promotes cancer progression (2016) (31)
Integrative molecular profiling of routine clinical prostate cancer specimens. (2015) (30)
Xenoestrogen action in breast cancer: impact on ER-dependent transcription and mitogenesis (2006) (30)
Hepatocyte growth factor/scatter factor promotes a switch from E- to N-cadherin in chick embryo epiblast cells. (1999) (30)
Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non–Small Cell Lung Cancer (2018) (30)
Cell-cycle-dependent regulation of androgen receptor function. (2015) (30)
MyoD-positive epiblast cells regulate skeletal muscle differentiation in the embryo (2006) (29)
Separation of phenotypes in mutant alleles of the Schizosaccharomyces pombe cell-cycle checkpoint gene rad1+. (1995) (28)
Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer. (2017) (28)
Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types (2019) (28)
Epiblast cells that express MyoD recruit pluripotent cells to the skeletal muscle lineage (2004) (26)
USP22 functions as an oncogenic driver in prostate cancer by regulating cell proliferation and DNA repair. (2019) (26)
DNA Damage Response in Prostate Cancer. (2019) (25)
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy (2019) (24)
Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer (2008) (24)
RB/E2F1 as a master regulator of cancer cell metabolism in advanced disease. (2021) (24)
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors (2019) (23)
Noggin producing, MyoD-positive cells are crucial for eye development. (2009) (23)
Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies (2019) (23)
Practical guide to the use of radium 223 dichloride. (2014) (23)
Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis (2009) (22)
p34cdc2 kinase activity is maintained upon activation of the replication checkpoint in Schizosaccharomyces pombe. (1996) (22)
The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness (2014) (21)
Cells that express MyoD mRNA in the epiblast are stably committed to the skeletal muscle lineage (2007) (21)
Myo/Nog cell regulation of bone morphogenetic protein signaling in the blastocyst is essential for normal morphogenesis and striated muscle lineage specification. (2011) (20)
Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities (2020) (19)
The role of tumor suppressor dysregulation in prostate cancer progression. (2013) (19)
Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer (2019) (19)
Consequence of the tumor-associated conversion to cyclin D1b (2015) (18)
Abiraterone + prednisone (Abi) +/- veliparib (Vel) for patients (pts) with metastatic castration-resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data. (2017) (18)
Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. (2006) (18)
Transcriptional Roles of PARP 1 in Cancer (2014) (18)
Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer. (2017) (17)
Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis (2010) (16)
Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. (2011) (16)
2,2-Bis(4-Chlorophenyl)-1,1-Dichloroethylene Stimulates Androgen Independence in Prostate Cancer Cells through Combinatorial Activation of Mutant Androgen Receptor and Mitogen-Activated Protein Kinase Pathways (2008) (15)
The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell (2014) (15)
Postprostatectomy radiation therapy: an evidence-based review. (2011) (15)
DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway (2019) (15)
Genetic Variation and Potential for Resistance Development to the tTA Overexpression Lethal System in Insects (2020) (15)
Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo (2017) (14)
Activation of TrkA tyrosine kinase in embryonal carcinoma cells promotes cell compaction, independently of tyrosine phosphorylation of catenins. (2000) (12)
An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy (2018) (11)
DNA-PKcs: A Targetable Protumorigenic Protein Kinase (2021) (10)
Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer. (2020) (9)
Identification of ASF / SF 2 as a Critical , Allele-Specific Effector of the Cyclin D 1 b Oncogene (2010) (9)
Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression (2021) (8)
Integrative molecular profiling of routine clinical prostate cancer specimens. (2015) (8)
Mutant p53 elicits context-dependent pro-tumorigenic phenotypes (2021) (7)
Intrinsic and Extrinsic Regulation of the Development of Myogenic Precursors of the Chick Embryo (1996) (7)
Functional Roles of the E 3 Ubiquitin Ligase UBR 5 in Cancer (2015) (7)
TCDD blocks androgen-dependent cell proliferation of LNCaP cells through modulation of RB phosphorylation * (2004) (7)
Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. (2021) (6)
A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer (2021) (6)
AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy (2014) (5)
Relevance of pRB Loss in Human Malignancies (2021) (5)
Erratum: Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis (Cell Death and Differentiation (2009) 16 (1408-1417) DOI: 10.1038/cdd.2009.86)) (2010) (5)
Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. (2017) (5)
Cotargeting AR signaling and cell cycle: A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone sensitive prostate cancer (mHSPC). (2018) (5)
Androgen Mediated Regulation of the G1-S Transition in Prostate Cancer (2002) (4)
Cyclin D1 goes metabolic (2012) (4)
Introduction to the 2019 Philadelphia Prostate Cancer Consensus Program: 'Implementation of Genetic Testing for Inherited Prostate Cancer'. (2019) (4)
A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer (2022) (4)
Androgen-mediated Control of the Cyclin D1-RB Axis: Implications for Prostate Cancer (2008) (4)
Assessing the Coverage of US Cancer Center Primary Catchment Areas (2022) (4)
Double Trouble: Concomitant RB1 and BRCA2 Depletion Evokes Aggressive Phenotypes (2020) (4)
Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC). (2020) (4)
c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study. (2018) (4)
The American Cancer Society and patient navigation: Past and future perspectives (2022) (3)
The SAGA complex regulates early steps in transcription via its deubiquitylase module subunit USP22 (2021) (3)
IGF2 revs the steroidogenesis engine. (2013) (3)
A novel small molecule inhibitor of p300/CBP for the treatment of castration-resistant prostate cancer: Preclinical evaluation. (2017) (3)
Hormone Whodunit: Clues for Solving the Case of Intratumor Androgen Production (2014) (3)
A syndrome of hereditary tyrosinemia in mink (Mustela vison Schreb.). (1979) (3)
The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology (2021) (2)
Relationship between the loss of the retinoblastoma tumor suppressor and radiosensitivity. (2011) (2)
Human Cancer Biology Cyclin D 1 Splice Variants : Polymorphism , Risk , and Isoform-Specific Regulation in Prostate Cancer (2009) (2)
Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi‐phased study of prostate cancer (2021) (2)
The AR-DNA repair axis: insights into prostate cancer aggressiveness. (2019) (2)
SLC 36 A 1-mTORC 1 signaling drives acquired resistance to CDK 4 / 6 inhibitors . (2019) (2)
c15-162: Phase IB trial of radium 223 and niraparib in patients with castrate resistant prostate cancer (NiraRad). (2018) (2)
598P A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC) (2021) (1)
A tale of three PKCs (2011) (1)
Androgen Receptor Regulation of Prostate Cancer Progression and Metastasis (2011) (1)
Leveraging RB status to define therapy for castrate-resistant prostate cancer. (2014) (1)
c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression. (2018) (1)
Abstract 2362: Long non-coding RNA NORAD interaction with miR-346 impacts DNA damage response and anti-tumor immunity in prostate cancer (2021) (1)
Molecular underpinnings of RB status as a biomarker of poor outcome in advanced prostate cancer. (2020) (1)
Splice Variants and Phosphorylated Isoforms of Cyclin D1 in Tumorigenesis (2018) (1)
An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy (2018) (1)
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer. (2022) (1)
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer (2022) (1)
A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer. (2015) (1)
Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA. (2022) (1)
Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset. (2019) (1)
Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). (2016) (1)
Gene Profiling Analysis of Androgen Receptor Mediated Function (2008) (1)
Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. (2018) (1)
Therapeutics , Targets , and Chemical Biology USP 22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression (2013) (1)
Abstract LB-185: A PSMA-directed natural killer cell approach for prostate cancer immunotherapy (2017) (1)
Abstract 1706: Impact of PARP1 on AR signaling and therapeutic response in prostate cancer (2010) (1)
Abstract IA26: Dual functions of PARP1 in prostate cancer: mechanisms and implications for therapeutic intervention (2017) (1)
There and Back Again: The Middle Earth of DNA Repair (2016) (1)
Caloric Restriction Augments the Molecular Effects of Radiation in Both Hormone-Sensitive and Hormone-Insensitive Prostate Cancers by Decreasing Inflammation (2016) (1)
Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer (2021) (1)
AACR Calls on Congress to Take Immediate Action Against COVID-19 and Protect Patients with Cancer During the Pandemic. (2020) (1)
Cancer Care at the Beginning of the COVID-19 Pandemic (2022) (1)
Kinase Activation Metastasis via Enhanced Extracellular Signal-Regulated N-Cadherin Signaling Potentiates Mammary Tumor (2007) (0)
Abstract 2853: Investigating DNAPK as a biomarker and a novel therapeutic target in aggressive prostate cancer (2015) (0)
Abstract 1859: Discerning the molecular basis of DNA-PK pro-tumorigenic functions and translational capacity as a therapeutic target in prostate cancer (2015) (0)
Abstract A12: Developing PDeX (Patient Derived Explant) to determine the basis for response to AR-directed therapeutics (2016) (0)
Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC). (2019) (0)
Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC). (2020) (0)
Patient-Level DNA Damage and Repair Pathway Profiles Are Prognostic After Prostatectomy for High-Risk Prostate Cancer (2015) (0)
Abstract 5874: Cdk4/6 kinase inhibitor resistance in prostate cancer (2017) (0)
Abstract A50: Cyclin D1 isoforms selectively manipulate AR signaling to promote metastatic phenotypes in early and castration-resistant prostate cancer. (2012) (0)
Title: RB1 Heterogeneity in Advanced Metastatic Castration Resistant Prostate Cancer Running Title: RB1 heterogeneity in mCRPC (2018) (0)
Abstract 1217: Determining the impact of CRPC-specific p53 mutation on therapeutic response and prostate tumor progression (2015) (0)
Abstract 5054: Discerning the PARP-dependent AR cistrome/transcriptome in prostate cancer (2015) (0)
Abstract 1860: DNA-PK-mediated transcriptional regulation drives tumor progression and metastasis (2015) (0)
Synergistic effects of the PARP inhibitor olaparib and pharmacological ascorbate in castration-resistant prostate cancer. (2019) (0)
Significance of distinct specifically enriched missense TP53 mutations in prostate cancer. (2020) (0)
Mechanisms of Disease Progression and Treatment Resistance in Prostate Cancer (2013) (0)
Abstract LB-030: Specific missense mutations inTP53elicit contrasting biochemical and biological outcomes affecting prostate cancer progression (2017) (0)
Targeting DNA repair-AR crosstalk dysfunction in advanced prostate cancer (2018) (0)
Abstract 4511: Prostate cancer-specific enrichment ofTP53missense mutations elicits differential, context-dependent biochemical and biologic outcomes (2019) (0)
Abstract A16: Potent and selective ATR inhibitors for the treatment of homologous-recombination deficient and PARPi-resistant cancers (2017) (0)
Differential response of prostate cancer cells to ionizing radiation: The RB status. (2012) (0)
PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer (2023) (0)
Hormonal Therapy for Prostate Cancer (2021) (0)
Influence of endogenous hormone and xenoestrogens on cytotoxic treatment in prostate cancer (2006) (0)
Abstract C94: Dual downregulation of Myc and AR with a sphingosine kinase-2 inhibitor prevents prostate cancer progression (2015) (0)
An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy (2018) (0)
Counterpoint-Prostate Cancer Genomic Analysis: Routine or Research Only? (2018) (0)
Effect of bypass kinase pathways on acquired CDK4/6 inhibitor resistance. (2018) (0)
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy (2019) (0)
Abstract 3878: Perturbations in the AR-cyclin D1 axis controls lethal tumor phenotypes in prostate cancer (2010) (0)
Abstract 1995: HuR dependent inhibition of PARG enhances PARP inhibitor therapy for DNA repair proficient and deficient pancreatic cancer cells (2016) (0)
Abstract LB-086: PARP-1 controls the DNA damage response by regulating E2F1 transcriptional activity (2017) (0)
Abstract LB-087: Stage specific re-calibration of E2F1 function after RB loss (2017) (0)
MP51-08 PRELIMINARY EXPERIENCE WITH COMPREHENSIVE GENOMIC PROFILING OF GENITOURINARY TUMORS; A TOOL TO DIRECT CLINICAL DECISIONS? (2018) (0)
Abstract IA9: Cross talk of the androgen receptor and DNA damage pathways: Molecular and translational prostate cancer relevance (2012) (0)
Differential response of prostate cancer cells to ionizing radiation: The RB status. (2012) (0)
Abstract 87: Targeting androgen receptor acetylation as a treatment for castrate-resistant prostate cancer (2015) (0)
Disclose and Manage Conflicts of Interest at Cancer Centers. (2020) (0)
Abstract 1851: Novel roles of DNA-PK in metabolic regulation in prostate cancer (2019) (0)
Validation of a genomic classifier for predicting biochemical failure following postoperative radiation therapy in high-risk prostate cancer. (2014) (0)
p 34 cdc 2 kinase activity is maintained upon activation of the replication checkpoint in Schizosaccharomyces pombe ( cyclin-dependent kinase / DNA synthesis / Radl / cell cycle / checkpoint control ) (2005) (0)
205 Validation of a genomic classifier for predicting biochemical failure following post-operative radiation therapy in high-risk prostate cancer (2014) (0)
The Second Great Lakes Nuclear Receptor Conference Memorial Union Sponsors and Acknowledgements the Endocrine Society Sponsoring Institution Corporate Sponsor Acknowledgements (2005) (0)
PARP-1 regulation of DNA repair factor availability. (2019) (0)
Abstract 1843: Novel actions of next-generation taxanes benefit advanced stages of prostate cancer (2015) (0)
Cytoskeletal Elements and Plasma Membrane Organization. Cell Surface Reviews, Volume 7.George Poste , Garth L. Nicolson (1983) (0)
Hus 1 p , a conserved fission yeast checkpoint protein , interacts with Rad 1 p and is phosphorylated in response to DNA damage (2013) (0)
Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC). (2017) (0)
Abstract 1574: Circadian clock gene expression and lethal prostate cancer outcomes (2019) (0)
Regulation of BMP signaling in the blastocyst by Noggin producing, MyoD-positive epiblast cells is critical for normal development (2010) (0)
Cells Determinant of Therapeutic Response in Prostate Cancer Retinoblastoma Tumor Suppressor Status Is a Critical (2007) (0)
Abstract LB-264: Preclinical evaluation of DNA-PK as a therapeutic target in prostate cancer (2017) (0)
D-type cyclin expression and localization in prostate cell xenografts and carcinomas (2006) (0)
Abstract 5217: RB loss reprograms AR and E2F1 signaling in models of prostate cancer progression (2019) (0)
Middlegame Theory, Cancer Style: A Message from the Editor-in-Chief (2012) (0)
Abstract 1449: Targeting CBP/p300 and its downstream transcriptional machinery in advanced prostate cancer (2023) (0)
Abstract C15: RB status alters the response of prostate cancer to ionizing radiation (2012) (0)
Abstract LB-085: RB loss-induced genome wide E2F1 reprogramming drive advanced prostate cancer (2017) (0)
NovelActionsofNext-GenerationTaxanesBenefit Advanced Stages of Prostate Cancer (2015) (0)
MP79-01 VALIDATION OF A GENOMIC CLASSIFIER FOR PREDICTING CLINICAL PROGRESSION FOLLOWING POST-OPERATIVE RADIATION THERAPY IN HIGH-RISK PROSTATE CANCER (2014) (0)
Abstract LB-A29: Divergent mechanisms of transcriptional regulation by SAGA member and epigenetic modifier USP22 (2018) (0)
Transcriptional silencing of Tyl elements in the RDNl locus of yeast (2011) (0)
Mechanistic study of the tumor suppressor role of MITF uncovers actionable translation targeting for prostate cancer (2019) (0)
Vol29#1_East-West Center International Fair (1995) (0)
Abstract IA03: Differential impact of RB pathway status on E2F1 reprogramming and disease progression in human prostate cancer (2018) (0)
Improving Genetic Pest Management Strategies: The Influence of Genetic Variation on the tTA Overexpression Lethal System & Development of a Male-only Strain of Spotted Wing Drosophila(Drosophila suzukii). (2018) (0)
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer (2022) (0)
Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in (2015) (0)
Abstract A08: PARP1-mediated E2F1 regulation of DNA repair capacity (2017) (0)
Validation of a Genomic Classifier for Predicting Metastasis Following Postoperative Radiation Therapy in High-Risk Prostate Cancer (2014) (0)
Abstract 1862: Discerning the role of USP22 in prostate cancer development and progression (2015) (0)
Effect of caloric restriction on the efficacy of radiation in both hormone-sensitive and hormone-resistant prostate cancers. (2016) (0)
Abstract SY29-01: Targeting DNA repair factor dysfunction in advanced prostate cancer (2017) (0)
Abstract A043: Bypass kinase pathways lead to acquired CDK4/6 inhibitor resistance in prostate cancer (2018) (0)
Abstract 1790: Caloric restriction can increase the efficacy of radiation in both hormone-sensitive and hormone-resistant prostate cancers by downregulating the IGF-1R pathway (2015) (0)
Hawaii in the Contemporary Pacific: The Proceedings of the Sixth Annual Pacific Islands Studies Conference, 1981 (1981) (0)
PARPi in PCa results in decreased availability of DNA repair factors. (2016) (0)
Targeting androgen receptor acetylation as a treatment for castrate-resistant prostate cancer (2015) (0)
Abstract 3576: USP22 modulates AR activity to critically regulate prostate cancer progression. (2013) (0)
Title: Targeting p300/CBP in lethal prostate cancer. Running title: Targeting p300/CBP in lethal prostate cancer (2020) (0)
Epiblast-Derived Skeletal Muscle Stem Cells Promote Eye Development (2009) (0)
Abstract 1071: Impact of AR activation status on the DNA damage response. (2013) (0)
Improving data accessibility: New strategies towards implementation of a genomic data portal. (2020) (0)
Targeting p300/CBP in lethal prostate cancer (2021) (0)
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair (2021) (0)
Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy. (2017) (0)
Endocrine-Related Cancer ( 2012 ) 19 1 – 12 mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer (2012) (0)
History of the Trust Territory of the Pacific Islands: Proceedings of the Ninth Annual Pacific Islands Conference (1985) (0)
AR function in promoting metastatic prostate cancer (2014) (0)
Fusing transcriptomics to progressive prostate cancer. (2014) (0)
Abstract 2982: Impact of the RB-pathway in breast cancer heterogeneity and therapeutic response (2011) (0)
Abstract IA24: Targeting DNA repair dysfunction in advanced prostate cancer (2018) (0)
Beyond the Cell Cycle: Implications of D-type Cyclin Deregulation in Prostate Cancer (2013) (0)
Leveraging the DNA damage and transcriptional-regulatory roles of PARP-1 as a means to improve prostate cancer therapy. (2014) (0)
Abstract LB-109: PDeX (Patient Derived eXplant) models to determine the basis for response to targeted agents in prostate cancer (2017) (0)
Abstract B11: Re-wired E2F function in response to RB loss as a potential driver of castration-resistant prostate cancer (2016) (0)
Abstract C8: Targeting the DNA-damage repair and transcriptional regulatory functions of PARP1 therapeutically in prostate cancer (2012) (0)
Abstract B040: Differential impact of RB status on E2F1 reprogramming in human cancer (2018) (0)
A novel MiR-346-Directed DNA damage mechanism is regulated by its interaction with long non-coding RNA, NORAD, in prostate cancer (2021) (0)
Can we Cure Cancer in Our Lifetime (2017) (0)
Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report (2016) (0)
Abstract B08: Retinoblastoma protein orchestrates cellular apoptosis in non-small cell lung cancer in response to CDK4/6 inhibition: novel targets and key mechanisms (2016) (0)
First Prospective Results Assessing the Clinical Utility and Clinical Benefit of Genomic Classifier Testing in Men Post-Prostatectomy (2019) (0)
Abstract B017: PARP-1 and E2F1 collaborate to transcriptionally regulate DNA repair factor availability (2018) (0)
The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc 1 , 2 (2017) (0)
Abstract IA06: Co-Targeting cell cycle and androgen signaling to personalize therapy for hormone dependent prostate cancer (2016) (0)
Genome wide analysis of AR-cell cycle interplay reveals novel functions in cancer (2015) (0)

This paper list is powered by the following services:

Other Resources About Karen E. Knudsen

en.wikipedia.org

What Schools Are Affiliated With Karen E. Knudsen?

Karen E. Knudsen is affiliated with the following schools:

Karen E. Knudsen's Academic­Influence.com Rankings